[Senate Hearing 115-844] [From the U.S. Government Publishing Office] S. Hrg. 115-844 PRIORITIZING CURES: SCIENCE AND STEWARDSHIP AT THE NATIONAL INSTITUTES OF HEALTH ======================================================================= HEARING OF THE COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS UNITED STATES SENATE ONE HUNDRED FIFTEENTH CONGRESS SECOND SESSION ON EXAMINING PRIORITIZING CURES, FOCUSING ON SCIENCE AND STEWARDSHIP AT THE NATIONAL INSTITUTES OF HEALTH __________ AUGUST 23, 2018 __________ Printed for the use of the Committee on Health, Education, Labor, and Pensions Available via the World Wide Web: http://www.govinfo.gov __________ U.S. GOVERNMENT PUBLISHING OFFICE 31-330 PDF WASHINGTON : 2020 -------------------------------------------------------------------------------------- COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS LAMAR ALEXANDER, Tennessee, Chairman MICHAEL B. ENZI, Wyoming PATTY MURRAY, Washington RICHARD BURR, North Carolina BERNARD SANDERS (I), Vermont JOHNNY ISAKSON, Georgia ROBERT P. CASEY, JR., Pennsylvania RAND PAUL, Kentucky MICHAEL F. BENNET, Colorado SUSAN M. COLLINS, Maine TAMMY BALDWIN, Wisconsin BILL CASSIDY, M.D., Louisiana CHRISTOPHER S. MURPHY, Connecticut TODD YOUNG, Indiana ELIZABETH WARREN, Massachusetts ORRIN G. HATCH, Utah TIM KAINE, Virginia PAT ROBERTS, Kansas MAGGIE HASSAN, New Hampshire LISA MURKOWSKI, Alaska TINA SMITH, Minnesota TIM SCOTT, South Carolina DOUG JONES, Alabama David P. Cleary, Republican Staff Director Lindsey Ward Seidman, Republican Deputy Staff Director Evan Schatz, Democratic Staff Director John Righter, Democratic Deputy Staff Director C O N T E N T S ---------- STATEMENTS THURSDAY, AUGUST 23, 2018 Page Committee Members Alexander, Hon. Lamar, Chairman, Committee on Health, Education, Labor, and Pensions, Opening statement......................... 1 Bennet, Hon. Michael F., a U.S. Senator from the State of Colorado, Opening statement.................................... 4 Witnesses Collins, Francis, M.D., Ph.D., Director, National Institutes of Health, Bethesda, MD........................................... 5 Prepared statement........................................... 8 Bianchi, Diana, M.D., Director, National Institute of Child Health and Human Development, Bethesda, MD..................... 14 Fauci, Anthony, M.D., Director, National Institute of Allergy and Infectious Diseases, Bethesda, MD.............................. 31 Hodes, Richard, M.D., Director, National Institute on Aging, Bethesda, MD................................................... 23 Sharpless, Ned, M.D., Director, National Cancer Institute, Bethesda, MD................................................... 29 QUESTIONS AND ANSWERS Response by Francis Collins to questions of: Senator Alexander............................................ 34 Senator Roberts.............................................. 37 Senator Young................................................ 42 Senator Enzi................................................. 44 Senator Collins.............................................. 45 Senator Burr................................................. 49 Senator Murray............................................... 52 Senator Casey................................................ 73 Senator Baldwin.............................................. 76 Senator Warren............................................... 77 Senator Kaine................................................ 79 Senator Smith................................................ 80 Senator Jones................................................ 81 PRIORITIZING CURES: SCIENCE AND STEWARDSHIP AT THE NATIONAL INSTITUTES OF HEALTH ---------- Thursday, August 23, 2018 U.S. Senate, Committee on Health, Education, Labor, and Pensions, Washington, DC. The Committee met, pursuant to notice, at 10:02 a.m. in room SD-430, Dirksen Senate Office Building, Hon. Lamar Alexander, Chairman of the Committee, presiding. Present: Senators Alexander [presiding], Isakson, Collins, Cassidy, Scott, Murray, Casey, Bennet, Murphy, Warren, Kaine, Hassan, Smith, and Jones. OPENING STATEMENT OF SENATOR ALEXANDER The Chairman. The Senate Committee on Health, Education, Labor, and Pensions will please come to order. Senator Bennet and I will each have an opening statement, and then I will introduce our witness, National Institutes of Health Director, Francis Collins. Then we will hear from Dr. Collins, and Senators will each have 5 minutes to ask questions. We have a vote at 10:30, not in the Committee but on the floor, and so we will continue straight through with the questioning. Senator Bennet, and I, and other Senators will share the presiding today so that we can continue the discussion. Not long ago, I ran into a friend from Vanderbilt University who is perhaps our largest contributor to cancer research there. This is what he said to me, ``Is it not a shame that the Congress is not doing anything to fund biomedical research?'' [Laughter.] The Chairman. This is how I replied to him. I said, ``In December 2016, Congress passed what Senator McConnell called, `The most important legislation of the year,' the 21st Century Cures Act. That Act gave the National Institutes of Health $4.8 billion for the Precision Medicine Initiative, the BRAIN Initiative, the Cancer Moonshot, regenerative medicine, as well as many new flexibilities and authorities to conduct the research that we hope will lead to breathtaking new medicines, treatments, and cures.'' That was thanks to Senator Blunt, Senator Murray, Senator Durbin, Senator Moran, and many other Senators. The Appropriations Committee is on track to provide record funding for the fourth year in a row to the National Institutes of Health. First, Congress increased N.I.H. funding by $2 billion in 2015; that is in addition to the Cures money. Then, we increased N.I.H. funding by $2 billion more in 2016. Then in 2017, Congress increased funding for the National Institutes of Health by $3 billion, including $500 million to work on a non- addictive painkiller. And today, we expect the full Senate to approve an additional $2 billion increase to N.I.H. funding for next year. This means, if the bill we hope the Senate approves today is signed into law, Congress will have increased funding for the National Institutes of Health by $9 billion since 2015, a 30 percent increase. The way we do our budgets here, that usually builds into the budgets over a longer period of time, that money, as a base. So if you counted over ten years, a $2 billion increase in one year means over ten years $20 billion in new spending authority. These increases have included the funding we intended to deliver on Cures. The purpose of this hearing is to make sure that money is being spent wisely. The reason Congress has devoted so much funding to biomedical research is well-captured in testimony that Dr. Collins gave before the Appropriations Committee a couple of years ago, when he offered ten ``bold predictions,'' as you called them then, Dr. Collins, of what we might be able to achieve in the next ten years if we continued to invest in research as we now have. Some of these predictions that you made then were: Being able to identify Alzheimer's disease before symptoms appear; The possibility we could rebuild a patient's heart with their own cells; The creation of a safe and effective artificial pancreas, making life easier and healthier for the millions of Americans with diabetes; Development of new vaccines, including for Zika and HIV/ AIDS, and the universal flu; Development of a new, non-addictive pain medicine, which may be ``the Holy Grail'' to dealing with the opioid crisis; Significant progress on the Precision Medicine Initiative, which aims to map the genomes of one million volunteers so we can better tailor treatments to individual patients; and, New treatments for cancer patients. Those are all the bold predictions. The two things I hope we keep in mind when we look at these large increases in funding that Congress has given the National Institutes of Health in recent years is first, it is hard to think of a major scientific advancement since World War II that has not been supported by Federal research funding. But we are not the only country that has figured that out. Other countries have seen that investments in basic research can lead to breathtaking new discoveries. Since 2007, China has increased its spending on basic science by a factor of four and may surpass the United States in total spending on research and development this year, according to Norm Augustine, who, during the George W. Bush administration, chaired the Rising Above the Gathering Storm group, the bipartisan committee that was charged with making recommendations about how to keep America's competitive advantage. The second thing I hope we keep in mind is that these large increases in funding for biomedical research, and other increases for national laboratories and other basic research, are not the part of the Federal budget that creates the huge national deficit. This spending, the spending we are talking about here, is part of the so-called discretionary spending, which is now roughly 29 percent of all Federal spending and includes the national defense, the national parks, the national laboratories, the National Institutes of Health among other things. Over the last ten years, this is the part of the budget that has grown at about the rate of inflation. Over the next ten years, according to the Congressional Budget Office, it is expected to grow at only a little more than the rate of inflation. So funding for research has been carved out of these budget limitations and is not the reason for the increasing Federal debt. What causes the Federal debt to increase is spending on entitlements, which according to the CBO, is going to squeeze funding for research, our national labs, and our national security over the next ten years. I have one other topic, Dr. Collins, I want to give you an opportunity to discuss. You recently told Senator Murray and me about an ongoing investigation into federally funded research, including, in some cases, research conducted by foreign nationals. I would ask you to take a few extra minutes in your opening presentation to brief the Committee on this issue. It is important to protect the integrity of research funded by the Federal Government. It is also important to recognize the role that scientists from other countries have played in research funded by the U.S. Government. For example, the director of Oak Ridge National Laboratory came to this country from India, before he became a citizen. The incoming director of the Los Alamos Laboratory came from Canada, before he became a citizen. The director of the National Renewable Energy Laboratory came from Germany before he became a citizen. Many graduate students at American universities, who work on N.I.H. grants, are foreign nationals legally in our country. And since 2000, thirty-three Americans, who were born in other countries, have won Nobel Prizes in Chemistry, Medicine, and Physics. I want to acknowledge the great advantage to our country of attracting the brightest people from around the world to our universities and laboratories as long as they follow the rules and conduct their research in appropriate ways. This is an issue that impacts more than just the National Institutes of Health and more than just this Committee's jurisdiction. But if there are some bad actors who are attempting to influence N.I.H.-funded research, we want to know about it, and we want to know what authority you need, or others need, to deal with it. Thank you. Senator Bennet. OPENING STATEMENT OF SENATOR BENNET Senator Bennet. Thank you, Chairman Alexander, for holding this bipartisan hearing on N.I.H.'s important work, including the agency's progress in implementing the 21st Century Cures Act. Dr. Collins, thank you for being here today and for your colleagues taking the time to be here to give us an update. In the last few decades, we have seen exponential advancements in medical research. The research community has developed cures and maintenance treatments for serious illnesses that used to be a death sentence. When I worked on the Breakthrough Therapies Act with Senators Burr and Hatch in 2012, we recognized the need to expedite treatments when early trials showed promises for conditions within an unmet need. We had no idea how successful the program would be. As of August 13, the FDA has approved 116 breakthrough therapy designated products. Many of these treatments show the promise of precision medicine. As N.I.H.-supported research has made clear, therapies that target specific genes or molecular pathways make it possible for providers to predict whether patients will respond to certain treatments. This Committee also recently worked to pass the RACE for Children bill to ensure that kids with cancer have the same access to targeted treatments that adults do. Pediatric oncologists at Children's Hospital Colorado are hopeful that they can launch as many as twenty-five new clinical trials because of the new law. These treatments will come from the research bench to the bedside, in large part, because of the great work happening at N.I.H. today. The 21st Century Cures Act included monumental policies to advance medical research. The hope of personalized medicine has already been a reality for some patients. I am looking forward to hearing more from Dr. Collins about the Precision Medicine Initiative and how we can reach even more Americans with therapies that maximize benefits and minimize toxic side effects. The 21st Century Cures Act also included the BRAIN Initiative, which will help researchers and the medical community grasp the intricacies of the human brain. Though we have gained a better understanding of how to treat different types of cancers or cystic fibrosis, the development of meaningful therapies for neurological diseases like Alzheimer's, Parkinson's, and ALS have lagged behind. I look forward to hearing about the progress on these initiatives. I am also interested to hear more about the work N.I.H. is doing to combat the opioid crisis, which continues to rip apart families and take lives in Colorado and across our country. This Committee has been active in working on an approach as a first step to respond to this epidemic, but there is so much more to do. With over 42,000 lives lost in 2016, and a preliminary estimate of almost 50,000 Americans in 2017, we still have much more to do. I want to thank the Chairman for raising the role of talent programs, and I am interested in hearing what you have to say on this subject, Dr. Collins. I would like to echo what the Chairman stated. Breakthroughs in medical research cannot happen in the silo of any one country, but we also want to ensure that we prioritize transparency and appropriately deal with bad actors who are taking steps that actually undermine the science and American efforts to do research. Thanks again to the Chairman, and the Ranking Member, and to Dr. Collins for being here today. I look forward to your testimony. The Chairman. Thank you, Senator Bennet. I am pleased to welcome Dr. Collins to today's hearing. Thanks to him for being here. He is overseeing the work of the largest supporter of biomedical research in the world. He has been the Director of N.I.H. since 2009. He is accompanied by Dr. Diana W. Bianchi, Director of the National Institute of Child Health and Human Development; Dr. Anthony S. Fauci, Director of the National Institute of Allergy and Infectious Diseases; Dr. Richard Hodes is Director of the National Institute on Aging; and Dr. Ned Sharpless, Director of the National Cancer Institute. We welcome Dr. Collins. Please give your testimony now. STATEMENT OF FRANCIS S. COLLINS, M.D., Ph.D., DIRECTOR, NATIONAL INSTITUTES OF HEALTH, BETHESDA, MARYLAND Dr. Collins. Chairman Alexander, Senator Bennet, and Members of the Senate HELP Committee. Thank you for giving me a little extra time to speak on this issue of protecting the integrity of U.S. biomedical research from undue foreign influence, which both of you have raised. N.I.H. is built on the bedrock principles of scientific excellence, unassailable integrity, and fair competition. N.I.H.'s commitment to these principles is unwavering. We have long understood, however, that the robustness of the biomedical research enterprise is under constant threat by risks to the security of intellectual property and the integrity of peer review. This knowledge has shaped our existing policies and practices. But through our own investigations, conversations with law enforcement, and even just from watching the press, we can see that the magnitude of these risks is increasing. Yesterday, I wrote to the senior representatives of more than 10,000 N.I.H. grantee institutions to request that they review their records for evidence of malfeasance in three areas of concern. First, failure by some researchers at N.I.H.-funded institutions to disclose substantial contributions of resources from other organizations including foreign governments, which threatens to distort decisions about the appropriate use of N.I.H. funds. Second, diversion of intellectual property; in grant applications or produced by N.I.H. supported biomedical research to other entities, including other countries. Third, is failure by some peer reviewers to keep information on grant applications confidential including, in some instances, disclosure to foreign entities or other attempts to influence funding decisions. While we, at N.I.H., depend on the major security agencies, and the Department of Health and Human Services's broader national security efforts, to protect our interests, N.I.H. and the U.S. biomedical research community at large have a vested interest in mitigating these unacceptable breaches of trust and confidentiality that could undermine the integrity of U.S. biomedical research. To help address this challenge, I am today announcing the new Working Group of my Advisory Committee to the director whose charge will be to identify robust methods to, first, improve accurate reporting of all sources of research support, financial interests, and affiliations. Second, mitigate the risk to intellectual property security. Third, explore additional steps to protect the integrity of peer review. But fourth, and importantly, to carry out these actions in a way that reflects the long tradition of partnership between N.I.H. and grantee institutions, and that emphasizes the compelling value of ongoing honorable participation by foreign nationals in the American scientific enterprise, which both of you have already highlighted in your opening statements. President M. Roy Wilson of Wayne State University and Dr. Lawrence Tabak, my principal deputy, will co-chair this group. The other members include President Jeffrey Balser of Vanderbilt University, President Ana Mari Cauce of the University of Washington, President Michael Drake of Ohio State University, President Wallace Loh of the University of Maryland, President Samuel Stanley of Stony Brook University, and Dr. Maria Zuber, Vice President for Research at M.I.T. The U.S. biomedical research enterprise is the envy of the world for the excellence of our discovery and innovation. Our leadership is made possible because the overwhelming majority of researchers participating on N.I.H. grants, whether U.S. or foreign born, are honest, hardworking contributors to the advancement of knowledge that benefits us all. We must move effectively to root out examples where our system is being exploited, but make sure to preserve the vibrancy of a diverse workforce that has played a major role in the American biomedical research success story. But just like in sports, it takes more than a good defense to win at science. It also takes a strong and talented offense. So if you will allow me for the rest of my testimony, I would like to focus on the 21st Century Cures Act and many other proactive ways in which you and your colleagues are helping to bolster N.I.H.'s tradition of success. I spend a lot of time with early stage researchers. Wherever I go, I set aside time to hear directly from them about their dreams, their ideas and, yes, their concerns. I know you, too, have met many of them both in your home states and on your much appreciated visits to N.I.H. I think it is critical that we all ask ourselves, what are we doing to foster this next generation of discovery? And what can we do to help our Nation remain the world leader in biomedical innovation? I believe the answers could be said to lie in certain key areas that we could call the five keys to success in science today. They are: a stable trajectory of support; a vibrant workforce; computational power; new technologies and facilities; and most of all, scientific inspiration. The good news is that thanks to you--Mr. Chairman, you have outlined what has happened in the last three years and perhaps the fourth year about to happen--early stage researchers are now seeing a stable trajectory of support. That provides such an encouragement to tackle difficult, challenging, high risk projects. Your work over the last three years is helping us to begin to reverse a distressing decade long decline in N.I.H.'s purchasing power for research, which is carried out in every state of the Nation. This year, we expect at the end of Fiscal Year 2018 to fund more than 11,000 new and competing grants; the largest number in history. The 21st Century Cures with its total funding of $4.8 billion over ten years for four signature initiatives is a critical part of this. A second key to success is a vibrant workforce. Success cannot lie simply in boosting the number of grants made. It must also include increasing the number of creative minds that are receiving those grants. So have a look at a new metric that we are using to evaluate success. This shows the trend in the number of individual principal investigators supported by N.I.H. over the past fifteen years. As you can see, that number is once again growing nicely. Note the surge that occurs around 2016, a surge that reflects when Congress began to change the trajectory of N.I.H. support and shows how that investment is paying off. The third key to success is computational power. This probably would not have been on my short list in 2009 when I started as N.I.H. Director, but like so much else, biomedical research has been transformed by the recent explosion in computing power and all of the big data it is generating. For example, the BRAIN Initiative, which you supported through 21st Century Cures, has created new imaging tools that are turning out droves of amazing data. And there is also data generated by structural biology, and the microbiome and the All of Us Research Program are part of the Precision Medicine Initiative, also supported by the Cures Act. On May 6, all of us began enrolling one million people living in the United States. Today, we are going to hit the 100,000 mark for volunteers. Nearly half of those are from communities historically underrepresented in medical research, providing a great opportunity to look at health disparity. To realize the full potential of these and other resources, we must also develop new technologies and facilities. Quite often, it is the technology itself that is driving the need for equally innovative facilities. Take the case of the new cell-based treatments, immunotherapy and gene therapy. Many involve removing cells from a patient's body using technology to reengineer those cells and then returning them to the patient. Many of our labs are not currently set up to handle these highly individualized processes, so it is crucial we make upgrades to keep pace. But now, onto my favorite: scientific inspiration. I can assure you that N.I.H.-funded researchers come to work every day full of innovative ideas and the wherewithal to see those ideas through, thanks to the Congress. Let me share just one example that really fits with the theme of this hearing, which is prioritizing cures. More than a decade ago, N.I.H. launched a special project on Spinal Muscular Atrophy, SMA, a tragic, inherited disease. As you see here, in its most severe form, it leaves babies floppy, unable to hold their heads up, feed well, and eventually even to breathe. Nearly all are deceased by fifteen months. Ten years ago, there was no treatment, but researchers had just discovered the DNA mutations that caused SMA. So N.I.H. supported more research, working closely with patient advocates and industry to move promising leads into therapeutic development. One of the most exciting comes from Jerry Mendell's team at nationwide Children's Hospital in Columbus, Ohio, which recently tested gene therapy for SMA in fifteen infants with severe disease. Again, these are infants not expected to survive more than fifteen months. They infused a viral vector designed to deliver the normal gene to the spinal cord, which is where the problem is and held their breath. Over the next few months, something truly dramatic happened. Like Evelyn Villarreal, who you see in this picture with her parents, 100 percent of the kids who got the highest dose of gene therapy were alive at twenty months. Nearly all could talk and feed themselves. And some, like Evelyn who is now three-and-a-half, not only can talk and walk, but she can even do pushups. Check out this video. [Video presentation.] Dr. Collins. I am very happy that Evelyn, her mom Elena, and her dad Milan, are here with us this morning. So please stand up, if you would, and say hello to the Members of the Committee. [Applause.] Dr. Collins. Evelyn, do you think you could do a twirl for us? I saw one earlier that looked pretty good; maybe a little too many witnesses. Well, does that not warm your heart? In closing, I am proud to lead N.I.H. at this time of unprecedented scientific opportunity and strong congressional support. The resources you have entrusted to us will be used to bring hope to untold numbers of patients and their families. We are the National Institutes of Health. But for many, like the Villarreal family, we are also the National Institutes of Hope. Thank you and we look forward to your questions. [The prepared statement of Dr. Collins follows:] prepared statement of francis s. collins Good morning, Chairman Alexander, Ranking Member Murray, and distinguished Members of the Committee. I am Francis S. Collins, M.D., Ph.D., and I have served as the Director of the National Institutes of Health (NIH) since 2009. It is an honor to appear before you today. Before I discuss NIH's diverse investments in biomedical research and some of the exciting scientific opportunities on the horizon, I want to thank this Committee for your sustained commitment to NIH to ensure that our Nation remains the global leader in biomedical research and advances in human health. As the Nation's premier biomedical research agency, NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and to apply that knowledge to enhance human health, lengthen life, and reduce illness and disability. As some of you have witnessed first-hand on your visits to NIH, our leadership and employees carry out our mission with passion and commitment. This extends equally to the hundreds of thousands of individuals whose research and training we support, located in every state of this great country, and where 81 percent of our budget is distributed. One of my personal priorities is developing the next generation of talented biomedical researchers. Last year, I shared with the Committee NIH's plans to build on our support for early stage investigators through a new initiative known as the Next Generation Researchers Initiative. NIH is developing evidence-based, data-driven strategies to assure that NIH investments are directed in ways that maximize scientific output. We are being aided in these efforts by an expert Working Group of the Advisory Committee to the Director, who will present recommendations in December 2018. But several important steps are already being taken: Institutes and Centers are placing greater emphasis on current NIH funding programs to identify, grow, and retain new-and early career investigators across these critical career stages. The Office of the Director is tracking progress across NIH in order to assess if these strategies are working. NIH remains committed to the development, support, and retention of our next generation of investigators. NIH is also committed to funding the highest priority scientific discoveries while also maintaining fiscal stewardship of Federal resources. Truly exciting, world class science is taking place. I would like to provide just a few examples of the depth and breadth of the amazing research NIH supports across the Institutes and Centers. The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is revolutionizing our understanding of the human brain, the most complex structure in the known universe. Launched in 2013, this large-scale effort is pushing the boundaries of neuroscience research. Ultimately, these insights will have profound consequences for the prevention or treatment of a wide variety of brain disorders. By accelerating the development and application of innovative technologies, researchers are producing a revolutionary new dynamic picture of the brain that, for the first time, shows how individual cells and complex neural circuits interact in both time and space. This picture is filling major gaps in our current knowledge and providing unprecedented opportunities for exploring exactly how the brain enables the human body to record, process, utilize, store, and retrieve vast quantities of information, all at the speed of thought. This year, the BRAIN Initiative will support critical areas including data infrastructure and sharing, the BRAIN Initiative Cell Census Network (which is developing an atlas of brain cell types), the Team Research Brain Circuits Program, and human brain studies. In human studies, the BRAIN Initiative is advancing brain imaging and non- invasive brain stimulation, and public private partnerships are investigating self-adjusting implanted brain stimulation therapies that are already showing promise. Ultimately, this will lead to an increased understanding of brain health, and a means of preventing brain disorders such as Alzheimer's disease, Parkinson's, schizophrenia, autism, and drug addiction. In April 2018, NIH launched the HEAL (Helping to End Addiction Long-term) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. NIH has and will continue to support cutting-edge research on new treatments for the millions of Americans with opioid addiction, and for the millions more with daily chronic pain. Both pain and addiction are complex neurological conditions, driven by many different biological, environmental, social, and developmental contributors. To build on this understanding, NIH will: explore new formulations for overdose reversal medications capable of combatting powerful synthetic opioids; search for new options for treating addiction and maintaining sobriety; continue to research how best to treat babies born in withdrawal through our ACT NOW study; develop new non-addictive treatments for pain through the study of novel targets and biomarkers; and build a new clinical trials network focused on pain. NIH, in partnership with the Substance Abuse and Mental Health Services Administration (SAMHSA), will also study how effective strategies for opioid addiction and overdose reversal can be put into practice in places severely affected by the opioids crisis through the HEALing Communities study. Thanks to your support, all hands are on deck at NIH for this public health crisis. Another exciting area of continued investment is in cancer immunotherapy, in which a person's own immune system is taught to recognize and attack cancer cells. After years of research supported by NIH, immunotherapy is leading to cures of some cancers like leukemia, lymphoma, and melanoma. But other cancers, particularly solid tumors like colon, pancreas, breast, and prostate, have proven much less responsive. I am excited to tell you that some of those barriers may be ready to come down. Just last month, a team led by NIH's Dr. Steve Rosenberg announced a novel modification of an immunotherapy approach that led to a complete regression, most likely a cure, of widely metastatic breast cancer in a woman with this previously fatal form of the disease. As always, I must counsel patience--this immunotherapy success story for solid tumors involves very few cases right now, and must be replicated in further studies. But, without doubt, this woman's life-saving experience represents hope for millions more. As exciting as potential cures like this can be, NIH is focused on advancing not just cancer therapies, but also cancer care. I would like to tell you about an NIH-funded trial that beautifully illustrates the progress we are making in this area. Each year, as many as 135,000 American women who have undergone surgery for the most common form of early stage breast cancer face a difficult decision: whether or not to undergo chemotherapy to improve their odds. Now, thanks to a large, NIH-funded clinical trial, called TAILORx, we finally have some answers. It turns out about 70 percent of such women actually do not benefit from chemotherapy, and a genomic test of tumor tissue can identify them quite reliably. Clearly, it is best to spare women from the potentially toxic side effects of these drugs, if at all possible. Furthermore, the ability to limit the use of chemotherapy to the 30 percent of women who will really benefit can yield significant cost savings for our health-care system, as much as $1.5 billion a year. Indeed, figuring out what health approaches work best for each individual--and why--is the goal of another important NIH Initiative: the Precision Medicine Initiative (PMI). Precision medicine is a revolutionary approach for disease prevention and treatment that takes into account individual differences in lifestyle, environment, and biology. While some applications of precision medicine have found their way into practice over the years, this individualized approach is simply not available for most diseases. The All of Us Research Program, a key component of PMI, is building a national resource--one of the world's largest, most diverse biomedical data sets in history--to accelerate health research and medical breakthroughs, enabling individualized prevention, treatment, and care. All of Us will enroll one million or more U.S. volunteers from all life stages, health statuses, races/ethnicities, and geographic regions to reflect the country's diverse places and people to contribute their health data over many years to improve health outcomes, fuel the development of new treatments for disease, and catalyze a new era of evidence-based and more precise preventive care and medical treatment. Across the Nation, NIH has engaged ten large health provider organizations, six community health centers, and the Department of Veterans Affairs to be our partners in this ambitious study. The program has funded over thirty community partner organizations to motivate diverse communities to join and remain in the program, with a focus on those traditionally underrepresented in biomedical research. We began a robust, year-long beta testing phase in May 2017, during which each of our partners were able to test their systems and processes to ensure a good experience for participants and ensure that the security of the data systems was of the highest possible order. I am happy to tell you that All of Us launched nationally on May 6, 2018 with events across the country to mark the program's open enrollment. As of August 15, 2018, almost 100,000 individuals have started the enrollment process, and over 50,000 have completed all the steps in the protocol. Of those almost 50 percent are from racial and ethnic groups who have been historically underrepresented in biomedical research. Following the national launch, we continue to improve and adjust the program based on participant feedback and emerging scientific opportunities and technological advances. We also are currently building the All of Us data resource, which is designed to be used by a broad range of researchers to study complex risk factors, support ancillary studies and clinical trials, and link to other large data sets. All of Us will be critical to realizing the promise of personalized medicine. We have never witnessed a time of greater promise for advances in medicine than right now. Your support has been critical, and will continue to be. Thank you again for inviting NIH to testify today. I look forward to answering your questions. ______ The Chairman. Thank you. We will begin a round of five minute questions. As I mentioned earlier, we have a vote in a few minutes, but we will continue right through that, and pass the presiding responsibility around. First, to Evelyn and to her parents, thank you so much for coming. It is a wonderful story, and that is the reason we are so interested in the work that Dr. Collins and his associates do. Thanks to Dr. Collins's team for being here. Dr. Collins, let me ask you to talk a little more about some areas you mentioned. With all this new money, and it is a lot, a 30 percent increase in a short amount of time, there are three areas that, in my conversations with researchers around the country, they suggest that we could do a better job of, and maybe you already are and we just do not know about it. So let me tell you about those three areas and see what you say. Number one, support more young scientists. Now, you talked about it there. But the feeling is if whatever money, even if it is a lot of money is available only to the established figures, that it discourages the brightest of the youngest scientists who often do some of their best work of their lives in their early years. We have included that in our legislation that we passed. You have made a focus of it. So I would like to know, number one, about the progress you are making and what else you intend to do about making sure that a lot of this money is focused on young scientists. Number two, the peer review panels, some have said to me that the peer review panels are not as high quality as they once were. I do not know if that is true or not. The suggestion was made that anyone who receives an N.I.H. grant, and there are a lot of those, I think you said ten thousand? Dr Collins. Eleven thousand. The Chairman. Eleven thousand, has to sort of go into the jury pool and be eligible to be selected. They might not all be the very best, but be eligible to be selected for the peer review panel. The quality of the peer review panels would be my second question. The third question would be, I have heard some criticism that the proposals have become more conservative, and more bureaucratic, and longer. That at one time, proposals before the peer review panels were shorter, more succinct, and bolder. What about those three things? What are you doing about them? What is the validity of concern in those areas? Dr. Collins. Well, those are three wonderful questions and I am glad to respond because they resonate with things that we talk about and are doing things about at N.I.H. With regard to young scientists, totally agree with you that this is critical. This is the future and we have gone from 2003 to 2015 through a tough time for those young scientists where N.I.H.'s purchasing power dropped way back and their likelihood of getting funded got to be to the point where many of them were really quite discouraged. We have benefited, of course, from congressional enthusiasm for N.I.H. over the last three years and that alone has helped, but we have actually prioritized the young investigators, what we call early stage investigators, to be the ones that we most want to be sure we are taking care of when they come forward with a new and wonderful idea. This year, in a program of next generation research initiative, which is actually part of 21st Century Cures, we expect to fund the largest number of early stage investigators ever; 1,100 of them who have never previously gotten a grant. We also have a very vigorous group, including some graduate students and post doctorates, and junior faculty, who are giving us additional ideas about how we could encourage those early stage folks. They will make a major set of recommendations to me in December, and I think that will add some additional new ideas about programs that we can do. We want to be sure that people not only see us as a place where they can bring their ideas, but they can bring bold ideas and we want to encourage that as well. Which is probably coming to your third, and I will come back to the second question, but the third question about conservatism in terms of applications, in terms of the kind of science that we fund. I also worry about that. We, at N.I.H., have been experimenting quite successfully in programs like the Pioneer Awards, which do not expect a lot of preliminary data, and a quite brief in the nature of the application, but need to propose something that is truly groundbreaking. With that program now having been in place for almost 10 years, I can tell you that dollar for dollar, it pays off better than our traditional programs and many of the institutes are adopting a similar program. The General Medical Sciences Institute has moved almost all their portfolio into that kind of program, which is a different model and we think is very productive. Finally, I would say with regard to peer review, we agree that anybody who has a grant from N.I.H. ought to be willing to serve on peer review. We did a survey of that three years ago and discovered there were some exceptions. As of 2015, it is a condition of your grant award that if you are asked to serve in peer review, you are expected to say yes. And the numbers I looked at over the last couple of weeks, those who are receiving funding from N.I.H., about 80 percent of them are, in fact, now serving in that role. That includes some younger folks, who maybe the older emeritus folks do not recognize as being sort of the familiar faces they thought they would see on a peer review panel, but we need them to be there too. The Chairman. Thanks, Dr. Collins. Senator Bennet. Senator Bennet. Thank you. Dr. Collins, just along the lines of Chairman Alexander's first question, I remember you sitting at, I think, at this very table some years ago talking about the cost of the unpredictability of the funding that N.I.H. was getting at the time, and the difficulty of being able to recruit and sustain academic research if the funding was uncertain. Can you tell us today with more certain funding what difference that is making on the ground in these research institutions around the country? Dr. Collins. It has made an enormous difference. And again, I think the difficult period from 2003 to 2015 made it hard for investigators to be confident that they could tackle a program that was going to take several years to bear fruit. It made it hard for us at N.I.H., as project managers and as visionaries, trying to design something bold. Could we really be confident that was going to happen? Let me say that 21st Century Cures was a wonderful antidote to that providing a trajectory for funding for those four signature projects over ten years. We have almost never had that kind of confidence in the future, and that bill made that possible for us to see. But for the average investigator working in the laboratory to see the way in which this stability has crept into the circumstance, as opposed to the ups and downs, has given them-- and I talk to a lot of them every day--the confidence that they are in the right place, doing the right thing, and it is Okay to tackle something that is not going to get solved in a year or two. I might say the way in which this is happening is such a different landscape now than the world's worst moment for us, which was sequestration, where in March 2013, all of a sudden, we lost $1.5 billion on one very bad day. That sent ripples through the community that took a long time to recover from, but I think we are getting there. Now let me say, we are still, I am sorry to say, at the point where if you send a grant to N.I.H. your likelihood of getting funded is only about 20 percent. That is a lot better than the 15 or 16 percent it was, but we are looking forward to being able to see ways to continue to see that rise. Senator Bennet. Good. I think that is a real testament to Chairman Alexander and Ranking Member Murray's bipartisan support of this Committee at a moment when we are not getting much of that in the U.S. Congress demonstrates that you can actually get some things done. Dr. Collins. We are deeply grateful for that. Senator Bennet. Well, we are grateful to you. I sent you a letter with Senator Schatz and asked you a few questions about whether there is a consensus in the scientific community on whether our society is becoming addicted to technology and what the public health effects of social networking are. Just last week, the American Psychological Association released a study showing that in recent years, 20 percent of U.S. teens reported reading a book, magazine, or newspaper daily for pleasure, while more than 80 percent said they use social media every day. Additionally, it reported in 2017, it found that children eight years old and older spent 48 minutes a day on mobile devices, up from 15 minutes in 2013. Similarly, 42 percent of children eight years old and younger have their own tablets, a major increase from 7 percent in 2013. It seems to me clearly we need to prioritize some research here in these areas. Thank you for your response to the letter, but I wonder whether you could talk about what N.I.H. is doing to address these issues? Dr. Collins. Well, I will quickly tell you about a program that is funded by N.I.H, called ABCD, the Adolescent Brain and Cognitive Development Program. This has enrolled now more than 10,000 nine and ten year olds and is tracking them over the course of ten years to see what influences are happening to brain development, including screen time, including the use of social media, including drug access, and many other things, including brain images that will teach us something about what is happening to the wiring. That is going to be very useful in this regard. But let me ask, Dr. Bianchi, of the Child Health Institute, because they have recently held an important workshop on this very issue trying to design what the next research steps ought to be. Dr. Bianchi. Thank you for your question. There are really two issues. There are issues on early child development and then there is the issue of technology addiction later on and how it affects adolescents. NICHD has recently held a workshop in January that has examined some of the neuropsychiatric issues on technology and early brain development. We are particularly concerned about language development, reading comprehension, and also parent- child interactions. We have come up with a number of recommendations to move forward with that and we are, of course, very interested in your legislation. Senator Bennet. Thank you. Thank you, Mr. Chairman. The Chairman. Thanks, Senator Bennet. I think the vote has started, so I am going to go vote and Senator Bennet, if you would chair the Committee. I will be back and we can swap the gavel. Senator Isakson. Senator Isakson. Thank you, Mr. Chairman. Dr. Collins, welcome. I want to add a comment, if I can, at the beginning rather than a question. My first engagement with you was at the National Prayer Breakfast when you demonstrated your gifted talent of playing classical music on the guitar, which to this day, was still one of the best performances I ever saw. But I knew then that you were a special person, and then with your success in the human genome, and all that you have done at N.I.H., we are blessed to have you. But I want to commend you on talking about the National Institutes of Hope. I have Parkinson's, and have had it, been diagnosed for six years. Evelyn, this child has a challenge and her family has a challenge. I am going to tell you about a challenge in our family in just a minute. But because you are the National Institutes of Hope, there are lots of people who have hope today that did not have it before primarily because you are changing attitudes in this country, both in the institution of medicine, as well as the patients who come in for help. I want to thank you for having such a positive, solution- based favorable attitude toward research, toward cures, and toward the process that nothing is impossible if we just work at it. You do a great job and we appreciate it. Dr. Collins. Thank you, Senator. Senator Isakson. As far as Evelyn is concerned, my daughter Julie's best friend is named Julia Vitorello. She is a resident of, was a resident of Washington, DC. She is now a resident of Colorado. Her baby was born with Batten disease, which is a totally incurable childhood disease which terminates life somewhere around the age of ten or twelve. But it is a degenerative disease like some of the other diseases that have a lot of atrophy involved in them. She is now at Boston Children's Hospital undergoing a special treatment that has been designed by her doctors who have hope of using gene therapy as a way to transmit and I am out of my league now. I am a real estate salesman. I do not know about the human genome. But I know this. They are using that gene therapy through the spinal column to get the treatment to the place in the brain it needs to be and they are showing an amazing success. You referred to the gene therapy and some other things. Would you talk about the gene therapy for just a minute? Dr. Collins. I would love to, Senator. And thank you for your comments. That was most generous. My colleagues make this job for me the most amazing experience every day because of the talent that you see surrounding me and all the other folks who are not at the table. Batten disease is one of those incredibly tragic neurological conditions which is caused by genetic misspellings. And so, it is amenable to the idea of gene therapy, but to actually turn that into practice has been decades long and it is very exciting to see this is now starting to work in certain instances. You saw an example with Evelyn because the disorder that affects her, SMA, affects the spinal cord. For a long time, we thought that would be the hardest place you could possibly imagine getting your gene therapy to be delivered, but you have seen what has happened here; just an amazing experience for all of us to see how this is working. With Batten disease, likewise, you need to get the delivery into the brain and the spinal cord. Hence, in the protocol you are talking about, the delivery is into the spinal fluid, which then bathes the brain and provides that delivery. I do not know the precise status of that protocol. I was gratified, though, to see similar circumstances about Huntington's disease. Now, here is one of those incredibly troubling, dominantly inherited conditions. Woody Guthrie, one of my childhood heroes, had Huntington's disease. In the last few months, again with the gene therapy placed into the spinal fluid, there is clear evidence that they are able to reduce the amount of the toxic protein; an encouraging evidence that it is slowing or stopping the progression of the disease. Now, that was one of the ones that I thought might be the longest to ever yield up its secrets because of it being affected in the brain this way. But we are starting to see that happen. None of that happened without many, many years of hard fought progress and a lot of disappointments, but now I think gene therapy is really coming into its own. Senator Isakson. I agree and it is showing great promise, which we hope we will see one day, just like we are seeing in Evelyn right now. Evelyn, thank you for coming, by the way; my kids always got the shies just like Evelyn does. One last thing to talk about is what you talked about on the brain. The stimulation in the human brain is now being done to treat Parkinson's and other neurological diseases and making remarkable improvements and remarkable increases. The more we can continue to invest in that, the more we are going to invest in, not cures, but certainly ways to deal with some of the ramifications of neurological disease. I want to thank all my colleagues on the Committee who helped me working on the Neurological Disease Registry expansion under the 21st Century Cures bill to expand that registry, to expand our information for research. Thank you very much for being here today. Dr. Collins. We do appreciate that. Again, the BRAIN Initiative, one of the early results of this is going to be having a better wiring diagram of the brain so the deep brain stimulation, which right now works, but we are not exactly sure why. We will be able to do it much more precisely. Senator Isakson. Thank you very much. Senator Bennet [presiding]. Thank you, Senator Isakson. Senator Kaine. Senator Kaine. Thank you to Dr. Collins and to all. I especially want to thank you, Dr. Collins. You are a great Virginian and you highlighted a wonderful Virginia family when you talked about Evelyn Villarreal. She and her family are from Centreville, I believe. Is that correct? Very, very happy to have you here and to hear the story about the genetic therapy that has made such an advance with respect to children with SMA. It also highlights the importance of pediatric specific research. I came onto the Committee and I probably had an assumption that research into adult conditions could be just kind of scaled to pediatric conditions. And so often, they are very different. In 2014, I was proud to support the Gabriella Miller KIDS First Research Act, which increased funding for research on pediatric disease within the N.I.H. by taking a separate, non- health related source of direct funding and putting it into pediatric research. And I think since that bill passed, it has directed about $55 to $60 million into pediatric conditions. There has also been improvements made for promoting such research in the 21st Century Cures Act to include the National Pediatric Research Network and the Global Pediatric Clinical Study Network. I would love it, Dr. Collins, if you could address this question. What promise do increasing research and the number of clinical trials in pediatric rare diseases or cancer hold for finding cures for diseases like SMA or like the childhood cancer that killed young Gabriella Miller when she was eleven years old? Dr. Collins. Well, I really appreciate the question. All of us at the table are deeply committed to advancing the cause of pediatric research. One of us happens to be a pediatrician and that is Dr. Dianna Bianchi. So I will ask her to address some of the points that you have raised, particularly about the Gabriella Miller KIDS First Research Act. Senator Kaine. Thank you. Dr. Bianchi. Thank you for your question. Always appreciate a focus on children. In fact, the N.I.H. funds $4.2 billion on pediatric research. Although we have child health in our institute name, research in pediatrics and pediatric conditions is done in virtually all of the institutes and we are all working together to make the best use of that $4.2 billion. We fulfilled a mandate of the recent Pediatric Research Network part that was in the Cures Act legislation by having four predominant networks that includes the IDeA States; the Pediatric Clinical Trials Network, which is focused on drugs, testing drugs in children; the Neonatal Research Network; and the Rare Disease Clinical Network, which is looking at over two hundred conditions. Those four networks are addressing many, if not most, of the conditions. Now the Gabriella Miller, we have had some successes in that area. I understand you knew Gabriella. Senator Kaine. I actually did not, but I know her parents very well. They were a great Loudoun County family. Dr. Collins. A wonderful family, I know them also quite well. Dr. Bianchi. The Gabriella Miller Network really creates an infrastructure so that researchers can collect large cohorts of biomaterials from children with conditions such as cancer and congenital anomalies. The infrastructure allows us to work at a very large scale and already has had successes. So we have a childhood cancer dataset that is already publicly available in pediatric Ewing's Sarcoma and we also have datasets that are available for congenital heart disease, cleft pallet, and diaphragmatic hernia. Researchers anywhere around the world can make use of that information. Senator Kaine. Thank you. Dr. Collins, one other question. You gave me an inspiring answer when you were before this Committee about a year ago--I used the analogy of President Kennedy saying we could be on the moon by the end of the decade, which seemed to many as science fiction, and yet it was doable and we did it--to ask you, could we, as a society make a pledge to be addiction free by 2030 and get there? You said not only could we, but we knew enough about addiction as long as we appropriately define what addiction free is, we should make such a commitment, and it was not a question about science or understanding. It was just really an issue of will and resources. I have continued to discuss that as I have traveled around the Commonwealth. Talk to me, if you can---- Actually, I am right near the end of my time. This is probably going to be a long answer. I think what I will do is I will submit for the record, you did address it in your opening testimony. I would love to know some of the things that you are doing at the N.I.H. to really help us grapple with this problem. As you know, just last week, the statistics came out; 72,000 Americans died of overdoses in 2017. Hundreds of thousands overdosed; 72,000 died. When I think that is more than the number of Americans that died in the entire Vietnam War, we are losing a war every year to despair and despondency, and your agency has a critical role in helping us figure out how to win that war. I will ask that question for the record to get status on current projects underway at the N.I.H. Dr. Collins. I would be happy to respond. We are very invested in this. The Congress gave us $500 million in the current fiscal year of additional funds to focus on the opioid crisis, and we are deeply engaged in that, and moving very quickly. Senator Kaine. Great, thank you so much. Thanks, Mr. Chairman. Senator Bennet. Thank you, Senator. Senator Cassidy. Senator Cassidy. Hello to you all. I would say gentlemen, but you too, Dr. Bianchi. Thank you all for being here. You probably know from previous kind of questioning, lines of questions, I have always been concerned about priorities in spending and so, just a couple of things as background. [Chart 1.] Senator Cassidy. The societal cost of disease here and you see that there is roughly, if this is disability life years adjusted and for my colleagues who may not be familiar with this, just an amalgamation. If somebody has an illness, how much do we lose in terms of productivity with an element of death. Then here is just the mortality. This is from 2015. The funding levels are from 2016. What we see as we look at societal costs of disease, there is roughly a correlation between how much it cost disease, how much it costs society, and the disability and the death rate it causes. I have two figures for obesity. One is how the CDC just says, ``These are the folks who die.'' And this is everybody for whom obesity is listed on the coroner's report knowing that obesity leads to a lot of other conditions that might be the primary cause of death, for example, heart disease. Can you hold up the other, please? [Chart 2.] Senator Cassidy. Here you see the N.I.H. funding and we see here is HIV, but obviously a lot for HIV. Here is diabetes. Societal cost. Although we spend a lot on diabetes, it is not as much. I am struck, though. What I want to emphasize is the obesity. Now, this scale cannot do justice to how much of a difference it costs society in terms of societal costs of obesity relative to funding. So there is the N.I.H. funding by disease where it is $965 million even though it costs us $190 billion. Again, it costs society, obesity, $190 billion, but we are spending $965 million. The size of the bubble represents how much money we are spending upon it. Can you hold up the racial disparity issue? [Chart 3.] Senator Cassidy. As some of you may know, I worked in a public hospital in Louisiana with the uninsured for thirty-five years and you cannot help but notice that there is a racial difference in obesity. If you look at race, any mention of obesity on a death certificate, African Americans have a much higher rate of obesity. American Indian or Alaskan Native, here is white, here is Asian Pacific. I think if we put Samoans, though, it would bend up like that. So there are some clear racial disparities associated with obesity. My question, is it just a function of how we appropriate money? Because it does seem that obesity as a primary illnesses is underfunded relative to the societal cost. Again, $190 billion societal cost, $965 million in contrast with some other diseases with far less societal cost, but far more N.I.H. funding, Dr. Collins. Dr. Collins. Well, Senator, it is nice to have another iteration of a conversation we have had over two or three years. I appreciate your perspective on obesity, which I totally agree, is an enormous public health challenge for our Nation. Senator Cassidy. By the way, can I just for those who may not know, obesity is implicated in Alzheimer's, implicated in heart disease, implicated in cancer. So although it may not be primary, it is the match that starts the fire for a lot of other diseases. I am sorry to interrupt. Dr. Collins. No, that is quite all right. I think your point is taken. The question that we, at N.I.H., are always wrestling with--and you have seen the way we have played this out in our strategic plan that we put forward a couple of years ago that tried to really articulate how we set priorities--is this balance between public health need and scientific opportunity. I think with obesity, we would all agree that the problem is a multi-factorial one. That there are many aspects of this that relate to things that N.I.H. probably cannot control in terms of diet, lifestyle, even the built environment, and so on. We are studying those things pretty intensively. In terms of interventions, though, to do something about this epidemic, which is a fairly recent one, it does not look as if a medical therapy is on the edge of happening. And so, it is a bit of a different circumstance than, say, HIV/AIDS where we have a vaccine. Senator Cassidy. If I may interrupt, Dr. Collins, in all due respect. In the past, you have told me, and I will not mention the institutes, but you have said, ``Well, we do not really fund that because we are really not on the cusp of great advances.'' I go speak to the director of the same, without mentioning your name, and he says, ``You have got to be kidding. We have so much opportunity here.'' That was kind of repeated several times. If I spoke to obesity researchers, they may start speaking about microbiomes, and leptin, and all this other stuff that again, kind of quickly passes my level of knowledge. But it does seem to be self-filling that if you say, ``We are not going to fund it because we are not ready to go to primetime in our research,'' you never go to primetime in your research because you never have the requisite prefunding. Dr. Collins. I think we are ready to go to primetime in research with obesity. It is a question of where are the scientific opportunities. You mentioned the microbiome. That is certainly a very powerful one. Clearly, learning things there plays out both in terms of obesity and diabetes, for which a big investment is being made. Although, some of that research might not actually score as obesity; it might score as it is a diabetes project or it is a nutrition project. Some of this, therefore, is just the bookkeeping part. But I take your point. Again, I think this is something we worry about every day when we meet as institute directors around the table on Thursday morning. Are we setting our priorities properly? Your input has been very helpful in that regard. Senator Cassidy. I would just suggest that we begin to focus more upon obesity, which seems to be an outlier in terms of lack of funding relative to societal cost. I now defer to whichever of my colleagues on the other side of the aisle is due. Senator Collins [presiding]. Senator Warren. Senator Warren. Thank you. The National Institutes of Health funds this country's top researchers and doctors. N.I.H. grants fuel medical breakthroughs, help universities pursue cutting edge science. I want to talk about money, because I understand N.I.H. needs money to be able to do its work. The vast majority of the N.I.H.'s funding comes from taxpayers. But in 1990, Congress established the Foundation for the National Institutes of Health, a nonprofit foundation that solicits private donations to support N.I.H. research. That means that if a drug company, or a device company, or a big tech company, or a lobbying firm wants to fund N.I.H. research, they can do so by donating to the N.I.H. Foundation. Dr. Collins, according to the most recent list of donors, the top six largest contributors to the Foundation for the N.I.H. are all drug companies. Each of these drug companies has donated to the Foundation every year for at least the past fifteen years. Let me just ask this question. Do you agree that science should be setting the agenda at N.I.H., and not donors? Dr. Collins. Absolutely. Senator Warren. Good. I understand that is how it is supposed to work. The N.I.H. comes up with a plan based on science and the Foundation gets donations to fund it, but when you have your hand out for cash, it is sometimes possible that these lines get blurred. The N.I.H. recently canceled a study of the health effects of alcohol consumption following an internal investigation that revealed that the alcohol industry was not only funding the study, but that the study had been set up to deliver the results the industry wanted. This is not even the only case this year that has raised ethical questions. In April, you pulled the plug on a plan to take hundreds of millions of dollars from drug companies that make opioids, some of which are under investigation for causing the opioid crisis in the first place, and using that money to fund a study to treat addiction. Let me ask this question, Dr. Collins. If these donations from industry are raising so many ethical questions, why should N.I.H. accept them at all? Dr. Collins. Well, we are thinking a lot about this in the wake of the examples that you have just cited. But as N.I.H. director of the last nine years, I can also cite you some examples where this kind of partnership with industry has actually made science move faster than it otherwise would have. Take the Accelerating Medicines Partnership, a project which involves ten pharmaceutical companies working on diabetes, on Alzheimer's disease, on rheumatoid arthritis, and very recently adding Parkinson's disease to that. In those instances, this was all precompetitive research. The data was immediately accessible. It brings around the same table scientists from both public and private sectors who design together what the research ought to be, building on the strengths of both groups. And it advances the cause of science more rapidly than might otherwise happen. There are no strings attached to the money that is provided by the drug companies, basically, that goes to the Foundation for N.I.H. It is used to support this program that is totally public about what we are doing. I would defend that. It has been a very good thing. What we need to be careful about, and which has, I think, caused us to stub our toe here a couple of times, is a circumstance where the source of the funds has a vested interest in a particular outcome of the study. We have started a recent study on cancer immunotherapy that Dr. Sharpless is leading. Again, involving industry input, trying to identify what are the biomarkers that indicate whether immunotherapy is going to work. Everybody wants to know the answer to that. Nobody has a stake in what the answer is going to be. Only that we need the answer. This is a really good example of how to work together. We just have to be thoughtful about exactly what the design looks like. Senator Warren. I appreciate that and I am really glad you are working to address the ethical landmines in this area. I think the N.I.H. should be getting more funding, but I will be blunt. If drug companies and rich donors want to chip- in for more N.I.H. research, they should do it through their taxes like everyone else. I would be happy to write the bill to bump up their contributions. But here is the bigger issue. Forcing an agency to beg for contributions for money just to carry out its essential mission is a glossy invitation for corruption. I believe it is time to end the influence of corporate money in Washington, and that means calling it out and shutting it down in whatever form it takes. Thank you very much. I appreciate the work all of you are doing. Senator Collins. Thank you. As luck would have it, I now not only get to be Chairman for a brief time, but I am up next for questions. [Laughter.] Senator Collins. Dr. Collins, it is always great to see you. I continue to claim you as my cousin and I hope you will not disabuse others. Dr. Collins. I am honored to be claimed. Senator Collins. The 21st Century Cures Act provided multiyear funding for the Regenerative Medicine Innovation Project. At MDI Biological Laboratory in Maine, researchers are working with a team from Jackson Labs in Maine and the Maine Medical Center Research Institute in an N.I.H.-led effort on kidney regeneration--Dr. Hodes may want to comment on this also--to address the high health care costs associated with treating chronic kidney disease. I visited the Maine Medical Center Research Institute, and it is absolutely fascinating the work that is going on. Could you tell us whether you are seeing any results yet from the Regenerative Medicine Initiative? I know it is early. Dr. Collins. I would love to talk about that and appreciate that this was included in 21st Century Cures as one of the four initiatives with specific call outs for extra funding. Certainly, this idea of being able to build whole organs from stem cells is one of the things that has really electrified a lot of the community. You could call this tissue engineering. What is happening with hearts and with kidneys is particularly of interest. If I had thought to put it in my briefcase today, I could have brought you a little kidney on a chip that has actually been synthesized by a different group, but very much working with the folks in Maine as well, because this is a very integrated community. The idea that we could figure out the appropriate kind of signals to send a stem cell that might have been derived from your skin and convince it that it should become your next kidney seems like science fiction, but maybe not so much. So far, these are pretty small renditions, but I have seen some of these that actually have a bit of a blood circulation. And even, if you will pardon me, can make a little bit of urine. So we are on the path here. Ultimately, what we hope is this could become an alternative to the need for a transplant for somebody whose kidneys have failed. And, of course, along the way, we learn a lot about normal kidney biology that maybe can keep peoples' kidneys from failing because we will have better signals about how to prevent that. Your group in Maine is a very important one in this effort. I am glad you have been by to see them. Senator Collins. It truly is miraculous work that they are doing and it is so exciting to me. As you are well aware, Dr. Collins, I have been the Founder and co-chair of the Senate Diabetes Caucus and the Alzheimer's Disease Task Force for many, many years. Dr. Collins. Yes. Senator Collins. As our population is growing older, we are seeing an increase of incidents in both those diseases. There is also some intriguing science that suggests that there may in some cases be a link between the two diseases as well as cardiovascular disease. Could you tell us what kinds of findings you are seeing in that area and what promising research is underway? Dr. Collins. That is a great question. I am going to ask Dr. Hodes---- Senator Collins. That would be great. Dr. Collins.----Our international expert on Alzheimer's who also knows a lot about diabetes to respond. Senator Collins. Thank you. Dr. Hodes. Thank you for that question, Senator Collins. There has been extensive collaboration with investigators interested in diabetes and those in neurodegenerative diseases such as Alzheimer's and related dementias. It has taken several forms and areas. It has been known for some time, for example, that diabetes is a risk factor for Alzheimer's disease. There have been metabolic parallels and similarities between diabetes and what goes on in the brain. In fact, some have called Alzheimer's disease a Type 3 diabetes because of an inadequate effect of insulin. It is perhaps most graphically translated now into a clinical trial that is ongoing using an intranasal route for introducing insulin to the brain to look for its impact on progression of Alzheimer's and cognitive decline. At the basic science level and now translated into real clinical trails, very much aware of the commonalities and ways in which we have to borrow and form across disciplines and across silos in order to best accomplish our goals. Senator Collins. Thank you very much. Senator Hassan. Senator Hassan. Well, thank you very much, Madam Chairman. Good morning to this extraordinarily distinguished panel. Thank you all for being here and thank you for the work you do. As you know, Dr. Collins, the fentanyl, heroine, and opioid epidemic is ravaging my State of New Hampshire and communities across our country. I was very proud to work with the rest of the New Hampshire delegation to secure a truly significant increase in funds for the Granite State to use for prevention, treatment, and recovery through the Substance Abuse and Mental Health Services Administration's State Opioid Response Grants. Now, New Hampshire is receiving $23 million for Fiscal Year 2018; before that, it was $3 million. So we think there is potential to really have an impact on the ground. I think it is really important that we stay focused on making sure that the hardest hit states, the states with the highest mortality rates, get the concentration of funds they need. But we also need to make sure that we are supporting science here because we need more and better ways to treat addiction and also to manage pain. It is a critical part of curbing the opioid crisis and I appreciate the conversations we have had about it. I also appreciate very much the work the N.I.H. is doing on the HEAL Initiative to advance this science. When you were before this Committee last, you explained that you needed more flexibility from Congress to allow the N.I.H. to fund research on the opioid epidemic more quickly and efficiently. Since that time, I have been really pleased to work with Chairman Alexander, with Ranking Member Murray, and Senator Young to introduce the Advancing Cutting Edge, ACE, Research Act to give the N.I.H. the flexibility it needs to quickly advance research on new treatments and non-addictive painkillers by providing them other transaction authority that we have talked about. Dr. Collins, how will the other transaction authority provided by the ACE Research Act help the N.I.H.'s work on the opioid epidemic including through the HEAL Initiative? Dr. Collins. Well, I appreciate the question and your support of this other transaction authority. Let me explain why it would be so useful and why the timing is really kind of urgent right now. Of the HEAL Initiative that you mentioned, HEAL standing for Help End Addiction Long-term. One of the projects that we are most excited about, which is truly ambitious, is to see if we could identify maybe three places in the Nation where a particularly hard hit circumstance is happening with opioids. Then bring together in a way that has not happened before, but as a research enterprise, all of the players in that--the primary care doctors, the emergency rooms, the police, the fire departments, the criminal justice system, all of the other support systems, the state health departments--and see what could we actually do if everybody worked together in a coordinated way to tackle this problem? No single one of those is going to be able to be successful in ending this terrible national crisis. To be able to do that, which has never really been attempted before, having the kind of flexibility where we could actually reach out and identify partners who maybe have never written an N.I.H. grant and say, ``We want you.'' Senator Hassan. Right. Dr. Collins. Also have a very active role at N.I.H. managing this effort in a fashion which, with grants, sometimes we cannot do. It would allow us to go faster and more effectively. We are going to try to do this anyway, but if we had other transaction authority, maybe in the next month, it would make a big difference in our ability to carry out that part of the HEAL Initiative. Senator Hassan. Well, I thank you for that. I am glad to see the bill passed the House and I hope the Senate will act soon on this---- Dr. Collins. I do too. Senator Hassan. ----Along with the entire opioid package that we passed out of this Committee. I want to go to one other New Hampshire issue, if I may, but again one that has applications all across the country. Families in my state continue to have questions about what PFAS contamination in drinking water means for their health and the health of their children. Once used for a variety of commercial and industrial applications, PFAS have seeped into water tables in many places, including New Hampshire. There is a critical need to better understand and address any potential adverse health effects the contaminants may have on our communities. Dr. Collins, what is the N.I.H. doing to study these chemical compounds and their potential health effects on Americans? Dr. Collins. Well, this is a significant environmental concern and I know in New Hampshire, there has been even a public discussion about it in Exeter that the E.P.A. came and led. Michigan is very much also caught up in this, particularly around Kalamazoo. Senator Hassan. Right. Dr. Collins. This is the kind of a substance that has a very long half-life. It is not naturally occurring, but has found its way into many groundwater and water supplies because of manufacturing of things such as carpet cleaners and so on. In terms of the environmental risks, we really do not know enough about the human risks to be very confident in saying whether this is really a big deal or whether actually we humans are able to handle it. We do know in animals, there is an association with immune consequences and maybe other things including, perhaps, cancer. But the human data is very uncertain. There is a big project which D.O.D. is funding which our NIEHS, National Institute of Environmental Health Sciences, is part of along with the C.D.C.'s ATSDR. That is going to, I think, provide the kind of data that we currently do not have, at least in terms of the epidemiology of what is the relationship of exposure and to human medical problems. We desperately need more information of that sort. Senator Hassan. I thank you and I agree with that. And I thank you for allowing me to go over, Madam Chairman. I am going to follow-up just to pinpoint any other gaps in research that you all might see, and I appreciate very much, again, all your work. Dr. Collins. Be glad to do it. Senator Collins. Thank you. Senator Smith. Senator Smith. Thank you, Madam Chairman. Thank you very much all of you for being here today. It is a very interesting panel. Though as is often the case, we are kind of coming and going from votes. If I have a moment, I would like to follow-up on the questions that Senator Hassan started. But I would like to start, actually, with something different. I want to start out by saying I really believe in the power of innovation in biomedical research. Coming from my home State of Minnesota, which is such a center of excellence both at the University of Minnesota and also Mayo Clinic. Senator Collins was talking about the power of regenerative medicine, which is also something that we have been working on intensely in Minnesota, especially through Mayo Clinic. So I believe very strongly in that. But I also believe that if people cannot afford the therapies and the medicines that we are imagining, that we are creating, then we have a real problem. I have to tell you that this is the No. 1 issue that I hear about from Minnesotans, whether it is figuring out how to pay for a therapy like insulin, which has been around for 100 years, to figuring out how to pay for the most recent cancer breakthrough medicines. It is a huge problem. A lot of these therapies, of course, have been created because of help from the National Institutes of Health. I am told that every one of the 210 new drugs approved by the FDA between 2010 and 2016, N.I.H. contributed to. What happens, of course, the cost of innovation is often the reason why medicines cost so much. Yet, in some ways, I think, taxpayers feel like they are paying twice. Once for the support to N.I.H. and then once again when they are asked to pay for these exorbitantly priced medicines when they show up at the pharmacy. Tell me a little bit about how you see the role of N.I.H. in helping to make sure that we do not only have innovation, but we also have innovation that people can afford. Dr. Collins. Obviously, this is a source of much discussion and much concern. I think you are echoing a lot of the views of the public about how this drug pricing issue is going to be wrestled to the ground and make it possible for people who need access to obtain that. We, at N.I.H., as you quoted this recent study, just published in the ``Proceedings of the National Academy of Sciences of the United States of America,'' where Fred Ledley and colleagues looked across a five-year or a six-year period and said every single one of the FDA-approved drugs in that timetable were based upon basic science discoveries that N.I.H. has supported. Some of those were basically to discover, ``Here is a drug target,'' and then a company went and made the drug that hit that target. So it is not as if we basically started making pills and somebody else---- Senator Smith. There is a difference between commercialization and basic research, which I understand. Dr. Collins. I think you could say that the system in the United States, this ecosystem between basic science, much of it supported by N.I.H., and commercial application has been the reason that we have been so successful in making medical progress. But the prices are certainly a concern. We do not have a lot of levers to pull in terms of direct influence on how a price is set for a newly innovated kind of therapeutic. What we do, and what we can do more of now because science is going forward, is to make it possible for the successes to happen more often. One of the reasons drugs are so expensive is that the failure rate for a company trying to get something across the finish line is about 99 percent. And so, when you finally get something that works, you have all of that other stuff that you have spent money on that got you nothing; that has to be somehow accounted for. At the National Center for Advancing Translational Sciences, which is part of N.I.H., we are identifying the areas that lead to that high failure rate systematically in coming up with new technologies to make that less likely to happen. If the success rate was just 5 percent instead of 1 percent, it would make a huge difference in the overall financial circumstances that companies face. We are pushing as hard as we can on that. That is probably our best contribution. Senator Smith. Well, I think that is an important issue for us all to work on together. It is basic access to these incredible therapies that are being created is fundamental to whether our health care system works at all. For those of us who watch this and try to understand it, and we understand what you are saying, but we also see that these big companies are making a ton of money, and yet, we are all paying. That is, I think, the fundamental issue that I am grappling with and trying to find solutions to. I would like to be able to--because innovation is so important and affordable drugs are so important--I would like to be able to work together on that. Mr. Chairman, I am out of time, but I would like to submit to the record and for follow-up a question having to do with what Senator Hassan was talking about. In Minnesota, we call it ``diseases of despair''. The significant uptick, 40 percent increase in suicide, and other diseases related to behavioral health, and opioids, and addiction. What we can do and how we can work with N.I.H. on that. Dr. Collins. Glad to. Senator Smith. Thank you. The Chairman [presiding]. Thank you, Senator Smith. Senator Jones. Senator Jones. Thank you, Mr. Chairman. Thank you, Dr. Collins, and the whole team for being here and for the incredible work you do that touches on every family in America. I really appreciate that. A couple of weeks ago, I had the privilege of meeting with some of the leaders at the University of Alabama in Birmingham, which I consider to also be one of the leading institutions of not only higher learning, but research in the country. Specifically not only have I met with them with a comprehensive cancer institute, and all the work that they are doing there, but I had a chance to talk about their precision medicine program. I know that everyone is excited about the All of Us Research Program because precision medicine truly has potential to be a game changer for delivering the right treatment to the right person at the right time. I am so happy that Alabama is playing a role. Dr. Collins, just a very general question, what is it Congress can do other than just continuing to try to fund at the levels--and I also commend Chairman Alexander and Ranking Member Murray about the work on this--is there something else specifically that we, as Members of Congress, can do to really help promote and accelerate the use of precision medicine in this country? Dr. Collins. I appreciate you raising this issue and mentioning the All of Us programs. In response to your ``what could we do?'' maybe it would be useful, in fact, for Congress to become an ally with N.I.H. in encouraging people to take part in this unprecedented national experiment where we are asking 1 million people to sign up. I think we mentioned, we just hit 100,000 today. So we have a little ways to go, but it is a really wonderful start. I appreciate the way in which UAB is a critical part of this partnership in the south. We can have people sign up either by direct volunteer, where they basically get online, JoinAllOfUs.org and sign up. Or, if they are nearby to one of the health provider organizations that is a partner with us and get their care there, they can sign up in that fashion. We are hoping to see this really go forward quite quickly. And any kind of assistance we could have in terms of local events to raise the enthusiasm for this. This is taking what we have learned from a program like Framingham, which taught us an awful lot about cardiovascular disease, and extrapolating it by about a factor of 40 in terms of the size, in covering all diseases, not just cardiovascular. Everybody sitting at the table has a stake in all of us turning out. We will enroll children starting next year as well. Senator Jones. I appreciate that and I will tell you, even before you said that, one of the things that I discussed with them at UAB was that at some point in the very near future that my wife and I will go, and we will sign up, and we will try to make an event of that. I will encourage all of my colleagues to do the same. Let me move on to one other question that I had and you touched on this earlier in your testimony in response to a question. That is about developing the next generation of talented biomedical researchers, which is an extraordinary effort, and I applaud that effort. But one of the things that I am concerned about is trying to reach into underserved communities. It seems that we are missing such talent that is out there whether they are researchers, or whether they are doctors, or lawyers. What can we do as part of the programs that we have got now to specifically reach into underserved areas to try to grab that talent out and give them that extra boost that they need? Because they do not always have the same chances as some of the kids in the more urban areas and schools that have a lot more money. Dr. Collins. Well, I really appreciate that point because this is an area of great interest and concern. N.I.H. has been working for decades in trying to increase the participation in our research workforce by people from all different backgrounds. And frankly, we have not been that successful in many of those decades in terms of making this happen. Our workforce is still underrepresented when it comes to African Americans, and Latinos, and Native Americans. But we have a couple of new programs that are now underway for about three or four years that are starting to show promise. One of them is to recognize that a lot of that talent does not necessarily end up in a research intensive four year college environment, but has the interest in getting involved in research. The thing that really makes that interest turn into a reality is the chance to take part in a real research project. Not hearing about it in a lecture hall, but actually doing research yourself. The program called BUILD, which we have started three years ago, is a partnership between universities that have a lot of underrepresented groups in their student body, but do not have the research opportunities that would really benefit. They partner up, with some funds from us, with institutions that do have those research capabilities to give those talented folks a chance to see what that is like. The other thing that is often missing is mentoring. If you do not see anybody who looks like you who is a role model, it is a lot harder when you hit a bump to imagine that this is your future. We set up a whole National Research Mentoring Network to connect people up. If you do not have somebody down the hall from you, well, maybe there is somebody in your town, or even in your state, or even just somebody you can talk to on the phone who has lived the life that you are trying to live. That seems to be a big encouragement too. We are evaluating this at every step along the way. I know this is a hard problem. I am not going to declare victory yet, but I am seeing real progress. Senator Jones. Well, thank you very much and thank you for your efforts. Thanks to all the Committee. I see my time is up, Mr. Chairman. I will probably have a couple of questions particularly about infant mortality and maternal mortality, which I think is something that is going underreported today. Thank you, Mr. Chairman. The Chairman. Thank you, Senator Jones. Senator Bennet. Senator Bennet. Thank you, Mr. Chairman. I just had a couple of remaining questions. Dr. Collins, after we passed 21st Century Cures, we worked on and were able to pass, thanks to the Chairman and the Ranking Member, the RACE for Children Act as part of the FDA User Fee package. I know that NCI has been collaborating with the FDA on the implementation. As you know, the bill directs pharmaceutical companies to study some of the most innovative cancer drugs for children when treatments are effective for adults and that may be a benefit for children. Some of the treatments maybe immunotherapies that use the body's own immune system to fight cancer. I understand that some of these therapies have been successful in treating certain pediatric cancers, yet other approaches have not been as effective. I wonder whether you could talk a little bit, Dr. Sharpless actually, about what NCI is doing to ensure children will benefit from promising advances in cancer immunotherapy. Dr. Sharpless. Thank you. This is an exciting area. As you alluded, there is a lot of progress going on in cancer research. A lot of new therapies have become available; a lot of excitement, a lot of new targets. But because of the structure of the commercialization of novel therapies, there is sometimes a disincentive, actually, to test these therapies in children. I think the RACE Act was laudably intended to encourage pharmaceutical companies to develop their drugs for pediatric use, in addition to adult use, when the target was relevant in children. I think it is a smart way to do it. I think it is not onerous on the drug companies. It does not hurt innovation, but it still provides a real emphasis on childhood cancer, which is an area where we had seen a lot of progress, but we still need a lot more. The RACE Act directed the NCI and the FDA to work together to develop a list of these relevant targets and that list is now developed through a series of meetings between the NCI and the FDA. It has been published online and it is seven pages of molecular targets that, if you are making a drug to this target, you have to have a plan to test it in children. Now, we eagerly await to see how this is implemented. We have every expectation the pharmaceutical companies will comply with this law and will really change their practices. Senator Bennet. Well, that is good to hear. Thank you very much. Finally, Dr. Collins, appreciate the update you provided on the Precision Medicine Initiative, particularly with respect to the All of Us Research campaign you were talking about. Saying it is going to give researchers a lot more data to predict prevention and treatment needs. As we begin to think about the future of precision medicine, I just wanted to know whether you think N.I.H. needs additional authorities to keep up with the fast pace of science. Researchers in Colorado have been at the forefront of some of these biomedical advances. There are more than 720 biomedical companies in my state employing almost 160,000 Coloradans through direct and indirect jobs, many of which, almost all of which actually pay extremely well. When we think about the hope of personalized medicine and the level of innovation we are seeing, what is the best way for us to follow-up on 21st Century Cures as we think about it? Dr. Collins. Again, I think what the 21st Century Cures bill provided over a very thoughtful two years of selecting and hearing from various stakeholders about what would be most useful did, in fact, incorporate from our perspective, a number of legislative authorities that we greatly value. There was a question from Senator Hassan about this other transaction authority being granted, our ability to use that in the common fund and to use it in the All of Us Precision Medicine Initiative has made a lot of difference in the ability to move quickly. We would actually be grateful to have an even broader authority for other transaction authority in other places. The Chairman and I have talked about that. As we have gotten more experience with it, it is perhaps more rapid moving. Maybe people worry it is a little bit riskier because it can be rapid moving, but in certain instances, has made all the difference. So that would be an area. Another area if we had the opportunity to expand our authorities, when we get to a place where we really have an opportunity to do an assessment of a precision medicine strategy, it is not interesting to the private sector. The ability to carryout Phase 3 trials within the National Center for Advancing Translational Sciences would be of value. At the present time, that is not something we have the authority to do. That is just another example of something that could help us. But again, I cannot say enough about the way in which 21st Century Cures basically took our list of things that we hoped to be able to do and pretty much checked the boxes one by one, and has made it so much more possible for us to move quickly. Senator Bennet. Thank you, and thanks to everybody. I actually cannot leave. I cannot resist asking Dr. Fauci, before we go, what are you worrying about these days? Dr. Fauci. Thank you for that question, Senator. As you probably would have guessed, I always worry about the emergence of an infectious disease such as we usually use the prototype of pandemic influenza, a respiratory illness that spreads rapidly and that has a high degree of morbidity and mortality. It is for that reason that I have been, and my colleagues and I have been, working on that for the last at least a decade, but more intensively over the last couple of years, on the development of a universal influenza vaccine that would not only be important to obviate the need to get a vaccine every single season and try to guess, hopefully correctly, what the next season's flu is going to be. But also to be able to immunize children at a very early age like we do with measles, mumps, and rubella to protect them from the possibility of an unexpected catastrophic outbreak like we saw in the pandemics that we have experienced. As a matter of fact, we have just very recently had a major meeting of individuals from throughout the country and world to help us formulate a strategic plan to develop a research agenda for the development of universal flu. You have asked Dr. Collins and I, many people do, when is this going to happen? We now have phases of Phase 2 and Phase 3 clinical trials that look very promising. And just literally in the next day or so, there is going to be an announcement from the University of Pennsylvania of a very, very interesting approach toward vaccines that involves recombinant DNA technologies that are really going to be very important. I have here just for your staff if you want it, a paper that we just recently published in the ``Journal of Infectious Diseases,'' which outlines our strategic plan for the universal influenza vaccine and our research agenda. That is what I worry about, but we are trying to do something about, but we are trying to do something about what I worry about. Senator Bennet. Thank you, Mr. Chairman. The Chairman. Thanks, Senator Bennet. Thank you, Dr. Collins, and to each of you for your extraordinary service to our country. Dr. Fauci, that was one of Dr. Collins's bold predictions about the universal vaccine and it is good to hear that it is on the way. We are glad to see a significant new and consistent source of funding directed toward the National Institutes of Health. But we want to make sure that we spend every single dollar as wisely and effectively as possible. We hope this hearing and other tools that we give you, either through 21st Century Cures or the authority to use money in different ways, if you will let us know what you need. Senator Bennet has been a leader in many of these bills. A lot of bipartisan support for breakthrough initiatives and we want to create an environment where you can succeed. The hearing record will remain open for 10 days. Members may submit additional information for the record within that time, if they would like. The HELP Committee will meet again on Wednesday, August 29 when we will hear from Dr. Scott Gottlieb, Commissioner of the Food and Drug Administration. Thank you for being here. The Committee will stand adjourned. QUESTIONS AND ANSWERS Response by Francis Collins to Questions from Senator Alexander, Senator Roberts, Senator Young, Senator Enzi, Senator Collins, Senator Burr, Senator Murray, Senator Casey, Senator Baldwin, Senator Warren, Senator Kaine, Senator Smith and Senator Jones [GRAPHICS NOT AVAILABLE IN TIFF FORMAT] ------ [Whereupon, at 11:28 a.m., the hearing was adjourned.] [all]